about
Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer.Predictive and prognostic values of Tau and BubR1 protein in prostate cancer and their relationship to the Gleason score.Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer.Sexual dysfunction in cancer patients: a review.The Role of Genetic Testing in the Selection of Therapy for Breast Cancer: A Review.Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels.Alveolar rhabdomyosarcoma originating from the uterine cervix.The Role of Body Mass Index in Triple Negative Breast Cancer.Fatal hepatitis B reactivation in an immune patient after anti-leukemic chemotherapy.Relation between hemostatic parameters and prognostic/predictive factors in breast cancer.Survival analysis of metastatic colorectal cancer patients who were treated with the five major therapeutic agents over the course of disease.Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.Self-measurement of blood pressure at home: is it reliable?The Impact of Subtype Distribution in Inflammatory Breast Cancer OutcomeThe prognostic value of thrombocytosis in newly diagnosed lung cancer patients: a retrospective analysisAdjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancerReply To the Editor, Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract, published online September 2014. DOI: 10.1177/1078155214551315Current Challenges Associated With Next-Generation Sequencing of Breast Cancer-ReplyCost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter StudyEvaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer
P50
Q34075052-7AC7736B-5B93-419F-9DA6-811BB3D419C1Q34615748-24AA269B-D5D0-4CDF-ADD1-779FA4B274C6Q36085860-E3134DC8-7DA6-4602-B740-D8255B1FA8DFQ38171780-4FD42839-419C-47AF-A456-2AE5EEE58E8EQ38937065-FF876D22-4BFD-4BFD-8205-13D9D0144C1AQ39381054-7574B216-638A-427D-8C29-FAE3D621DE42Q39746262-33669F0C-D447-43C2-88F5-0A93859A0790Q40448226-4E4A8787-53E3-4E67-A2EC-363DAF0A30A3Q43039052-0F6B41D0-A8F4-42B7-B2B7-F86ABCD26B2AQ44307385-27973411-A0DD-43CF-ABEB-ACC6E3B4D1F8Q44624924-0C590323-0648-4240-B038-63AC53EEF4BAQ45694936-CF263BDE-CA49-4E1A-BAEE-B1FCADF3B49BQ47623769-CDD36EBA-23B4-4DEA-BA15-5D24ACE08D7EQ57054849-787DFDA5-014D-4DD5-8B64-0FBFAC0DEE29Q83439778-A00CC030-75C2-4F32-A4D4-90A719D1A1FBQ85334290-393605A6-8B6A-4776-87E4-B1EABBFBE40EQ87318185-1F3571B2-A6D9-4333-A120-6670CFA09D19Q88099137-BFC8991B-E8A0-465C-8461-B84B90676EDAQ91943896-4B0C1001-2B5F-4C10-9FF1-9DB2FFF4CCBDQ95368550-43E7AAE2-C730-40ED-AC81-0A383C4931C4
P50
description
researcher ORCID ID = 0000-0003-3790-791X
@en
name
Burcu Cakar
@ast
Burcu Cakar
@en
Burcu Cakar
@es
Burcu Cakar
@nl
type
label
Burcu Cakar
@ast
Burcu Cakar
@en
Burcu Cakar
@es
Burcu Cakar
@nl
prefLabel
Burcu Cakar
@ast
Burcu Cakar
@en
Burcu Cakar
@es
Burcu Cakar
@nl
P108
P108
P31
P496
0000-0003-3790-791X